The institutional cluster is a strong bullish signal, particularly given the dominance of active managers and the actuarial amplifier flag for the offering+cluster combo. However, the lack of insider buying and the 45-day 13F reporting lag warrant caution. Monitor for any insider open-market purchases or further pipeline catalysts (ERAS-0015 data) that could confirm the thesis.
Drug in focus
ERAS drug pipeline →ERAS-0015
◆ Mixed Named in this fund cluster- Impact
- Phase
- Phase 1
- Time to market
- ~3-5 years, assuming registration-enabling trials initiate in 2027 and a potential approval by ~2029-2030
- Next catalyst
- None dated
What to watchERAS-0015 Phase 1 data is genuinely strong (57-62% response rates in difficult-to-treat tumors) but the stock carries heavy legal baggage, a securities class action and patent-infringement allegations from Revolution Medicines. The stock recovered from its April 48% crash to ~$18; watch for the August 10, 2026 lead-plaintiff deadline and any developments in the Revolution Medicines patent dispute, which could swing shares sharply. The registration-enabling trial initiations in H1 2027 are the next major de-risking catalyst.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 13 $17.86entry
- T+1 · 3mo ago +2.91%α +3.11% · $18.38
- T+5 · 3mo ago −4.37%α −2.40% · $17.08
- T+20 · 2mo ago −11.09%α −9.34% · $15.88
- T+60 · 11d ago −19.32%α −13.84% · $14.41
How similar events traded
Executive Summary
A strong institutional cluster formed in ERAS during 2026-Q2, with 16 buyers accumulating $104.2M net against just 1 seller trimming $4.5M. The buying is dominated by active asset managers, including three new positions from Capital World Investors ($12.9M), Assenagon ($14.9M), and Jennison Associates ($51.1M), the latter being the largest single new stake. This cluster follows a $550M follow-on offering 29 days ago, and the cross-filing actuarial verdict flags this combo (offering + institutional cluster) as a statistically significant amplifier.
Key Financial Metrics
Institutional Positions
Net institutional flow: $104.2M
▲ Buyers (16)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Jennison Associates | NEW | +0% | $51.1M | $51.1M |
| Assenagon Asset Management | NEW | +0% | $14.9M | $14.9M |
| Capital World Investors | NEW | +0% | $12.9M | $12.9M |
| Citigroup | DOUBLED | +1352.9% | $13.1M | $12.3M |
| Td Asset Management | ADD | +67.7% | $12.1M | $5.7M |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| JPMorgan | TRIM | -45.8% | $13.8M | -$4.5M |
Key Facts
- 16 institutions accumulated $104.2M net in ERAS during 2026-Q2
- Jennison Associates opened a new $51.1M position, the largest single buy
- Capital World Investors and Assenagon each opened new positions of $12.9M and $14.9M respectively
- Only 1 seller (JPMorgan) trimmed $4.5M, representing minimal sell-side pressure
- Cluster follows a $550M follow-on offering 29 days ago; cross-filing actuarial verdict flags this combo as an amplifier
- No insider open-market buying corroborates the institutional cluster
Financial Impact
16 institutional buyers accumulated $104.2M in net new positions, while 1 seller reduced holdings by $4.5M, resulting in a net inflow of approximately $99.7M
Risk Factors
- 13F data is 45+ days stale; the cluster may have already been unwound
- No insider open-market buying to corroborate the institutional thesis
- Recent $550M dilutive offering could cap near-term upside
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-ERAS-2026-Q2 |
Track record
26 reports on ERAS
4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 settles Feb 12
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 settles Feb 11
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 settles Feb 1
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 settles Jan 13
- Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 settles Nov 17
- Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 ▼ −14.61% −11.84% vs SPY
- Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Viewing Entry $17.86 to $14.41 ▼ −19.32% −13.84% vs SPY
- Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 ▼ −19.32% −13.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers